Recombinant Mouse BID Protein, N-His from ProteoGenix; catalogue ARO-P10569; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant Mouse BID Protein, also known as BH3-interacting domain death agonist, is a member of the Bcl-2 protein family. It plays a crucial role in regulating apoptosis, or programmed cell death, by promoting the release of cytochrome c from the mitochondria. This protein has been extensively studied for its structure, activity, and potential applications in various fields. In this article, we will delve into the details of Recombinant Mouse BID Protein, highlighting its structure, activity, and potential applications.
Recombinant Mouse BID Protein is a 195 amino acid protein with a molecular weight of 22 kDa. It is composed of three major domains: the BH3 domain, the α-helical domain, and the C-terminal domain. The BH3 domain, also known as the Bcl-2 homology 3 domain, is responsible for the interaction with other Bcl-2 family proteins. The α-helical domain is responsible for the insertion of BID into the mitochondrial membrane, while the C-terminal domain contains the death domain, which is involved in the activation of apoptosis.
Recombinant Mouse BID Protein plays a crucial role in the regulation of apoptosis. It is activated by various stimuli, such as DNA damage, growth factor withdrawal, and cytokine signaling. Upon activation, BID translocates to the mitochondria and interacts with other Bcl-2 family proteins, such as Bax and Bak. This interaction leads to the formation of pores in the mitochondrial membrane, resulting in the release of cytochrome c. Cytochrome c then activates caspases, which are enzymes responsible for the execution of apoptosis.
In addition to its role in apoptosis, Recombinant Mouse BID Protein has also been found to play a role in other cellular processes. It has been shown to regulate autophagy, a process that involves the degradation of damaged or unnecessary cellular components. BID has also been implicated in the regulation of cell migration and invasion, suggesting its potential role in cancer progression.
Recombinant Mouse BID Protein has a wide range of potential applications in various fields, including cancer research, drug discovery, and therapeutic development. Its role in apoptosis and other cellular processes makes it a promising target for cancer treatment. In fact, BID deficiency has been linked to increased tumor growth and resistance to chemotherapy. Therefore, targeting BID could potentially lead to the development of new cancer therapies.
In addition, Recombinant Mouse BID Protein has also been used in drug discovery and screening. Its ability to regulate apoptosis and autophagy makes it a valuable tool in identifying potential drug candidates for the treatment of various diseases. BID has also been studied for its potential role in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, and its potential as a therapeutic target for these conditions.
Furthermore, Recombinant Mouse BID Protein has been used in various research studies to understand its structure and function. Its recombinant form allows for easier purification and manipulation, making it a valuable tool for studying its role in apoptosis and other cellular processes.
In conclusion, Recombinant Mouse BID Protein is a crucial member of the Bcl-2 protein family, playing a significant role in regulating apoptosis and other cellular processes. Its structure and activity have been extensively studied, and its potential applications in cancer research, drug discovery, and therapeutic development hold great promise for future advancements in these fields. Further research on this protein will undoubtedly uncover more insights into its role in cellular processes and its potential as a therapeutic target.
ProteoGenix catalogue number ARO-P10569. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 23.48 kDa; Fragment: Gly8-Asp195; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
